MeSH D020178 - circadian rhythm sleep disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Apotex | Tasimelteon | Tasimelteon | 2022-12-20 | |||
| MSN Laboratories | Tasimelteon | Tasimelteon | 2023-01-12 | |||
| Teva | Tasimelteon | Tasimelteon | 2022-12-12 | |||
| Vanda Pharmaceuticals | Tasimelteon | Hetlioz | 2022-12-09 | 2014-01-31 | $77.333 M | Q3/23-Q2/24 |
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
50%1/2
Phase 3
33%1/3
Approved: 0Overall Success rate: 17%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use